70 results on '"Jones, Robin L."'
Search Results
2. Patient-Reported Outcomes and Tolerability in Patients Receiving Ripretinib versus Sunitinib After Treatment with Imatinib in INTRIGUE, a Phase 3, Open-Label Study
3. Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]
4. The biology and treatment of leiomyosarcomas
5. A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl)
6. Molecular profiling in desmoplastic small round cell tumours
7. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022
8. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
9. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
10. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
11. Correction to: Machine learning for rhabdomyosarcoma histopathology
12. Machine learning for rhabdomyosarcoma histopathology
13. Immune checkpoint inhibition in sarcomas: time to be histology-specific?
14. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
15. Management of Vascular Sarcoma
16. The perplexing role of immuno-oncology drugs in osteosarcoma
17. Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments
18. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
19. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study
20. Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry
21. Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit
22. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
23. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
24. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
25. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
26. Primary iliocaval leiomyosarcomas: The path beyond surgery
27. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial
28. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
29. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study
30. Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
31. Negative phase III trials announce the need for biomarkers in sarcoma
32. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
33. Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck
34. Olaratumab in soft tissue sarcoma – Current status and future perspectives
35. 2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma
36. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial
37. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
38. Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?
39. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies
40. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
41. Drug repositioning in sarcomas and other rare tumors
42. Redefining the standard of care in metastatic leiomyosarcoma
43. The Maternal Early Warning Criteria: A Proposal from the National Partnership for Maternal Safety
44. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics
45. Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth
46. Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
47. KIT signaling regulates primordial follicle formation in the neonatal mouse ovary
48. The Use of Radiofrequency Ablation in Gastrointestinal Stromal Tumor
49. MDM2 inhibition in liposarcoma: a step in the right direction
50. Molecular Classification of Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.